New hope for tiniest patients with rare hormone disorder
NCT ID NCT07187375
Summary
This study is testing a drug called crinecerfont in babies under 2 years old who have congenital adrenal hyperplasia (CAH), a rare genetic hormone condition. The main goal is to see how the baby's body processes the drug and to check if it is safe and well-tolerated. It is a small, early-phase study that will help researchers understand the right dose for this very young age group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL ADRENAL HYPERPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neurocrine Clinical Site
RECRUITINGBerlin, 13353, Germany
-
Neurocrine Clinical Site
RECRUITINGDüsseldorf, 40225, Germany
-
Neurocrine Clinical Site
RECRUITINGHeidelberg, 69120, Germany
Conditions
Explore the condition pages connected to this study.